Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals Limited announced a webinar to discuss the strong initial demand and performance of their newly launched product, Sofdra. This event, scheduled for July 8, 2025, will be led by key executives and aims to provide stakeholders with insights into the product’s market reception and its implications for the company’s growth and industry standing.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix, specializing in innovative treatments for skin conditions. The company has received FDA approval for Sofdra, a novel treatment for primary axillary hyperhidrosis, marking it as the first new chemical entity approved for this condition.
Average Trading Volume: 9,602,484
Technical Sentiment Signal: Sell
Current Market Cap: A$607.9M
See more data about BOT stock on TipRanks’ Stock Analysis page.